The gut microbiome has attracted substantial scientific interest as a potential contributor to CKD progression and as a therapeutic target in nephrology. The first systematic characterization of gut dysbiosis in CKD patients was reported by Vaziri et al. in the Journal of the American Society of Nephrology (2013), demonstrating marked depletion of beneficial short-chain fatty acid-producing bacteria and overgrowth of proteolytic genera in hemodialysis patients compared to healthy controls.
ISN (International Society of Nephrology) has highlighted gut-kidney axis research through its publications in Kidney International and through educational symposia. Disruption of intestinal barrier integrity in CKD, characterized by increased intestinal permeability and translocation of bacterial lipopolysaccharide, amplifies systemic inflammation and is reviewed comprehensively by Meijers et al. in the Journal of the American Society of Nephrology (2010).
Uremic toxins of gut microbial origin, including indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide (TMAO), accumulate in CKD patients due to impaired renal clearance. The landmark epidemiological study by Tang et al. (New England Journal of Medicine, 2013) established TMAO as an independent predictor of major adverse cardiovascular events in a cohort of over 4,000 patients, providing mechanistic plausibility for the gut-cardiovascular-kidney axis.
Dietary interventions targeting gut microbiota composition have been investigated in CKD populations. The KDOQI Nutrition in CKD guidelines (Ikizler et al., American Journal of Kidney Diseases, 2020) address dietary protein and fiber recommendations partly in the context of uremic toxin precursor availability. Small randomized trials published in Nephrology Dialysis Transplantation have shown that prebiotic fiber supplementation can reduce urinary p-cresyl sulfate excretion in pre-dialysis CKD patients.
The International Society of Nephrology acknowledges that clinical evidence for microbiome-targeted interventions in CKD remains at a preliminary stage. ISN’s research agenda, reflected in the World Kidney Day 2020 theme of ‘Kidney Health for Everyone Everywhere,’ emphasized the need for large-scale randomized controlled trials with robust clinical endpoints to determine whether microbiome modulation strategies can meaningfully alter CKD trajectories and improve patient outcomes.